Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 8/20 | 0.70 |
| ▸ | HEXB | P07686 | 8/20 | 0.70 |
| ▸ | DHFR | P00374 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12368257 | 0.90 | HEXA (0.64) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL8261006 | 0.83 | HEXA (1.00) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL19160148 | 0.82 | HEXA (0.55) | HEXAHEXBDHFRMEN1ALDH1A1 | |
| SCHEMBL12368245 | 0.80 | HEXA (0.77) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL12368249 | 0.78 | HEXA (0.72) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL7160819 | 0.77 | HEXA (0.50) | HEXAHEXBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1885367 | 0.77 | HEXA (0.50) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL6667206 | 0.77 | HEXA (0.59) | HEXAHEXBDHFRMEN1SLC22A1 | |
| SCHEMBL15392107 | 0.77 | ADORA2A (0.54) | HEXAHEXBDHFRMEN1ALDH1A1 | |
| SCHEMBL8488614 | 0.77 | HEXA (0.50) | HEXAHEXBDHFRMEN1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014307-A2 | GAL3 ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014376-A1 | GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363638-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | Synaptic Pharmaceutical Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
| WO-2002060392-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | HEXA 164/4885HEXB 199/4885DHFR 3047/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | HEXA 164/4885HEXB 199/4885DHFR 3047/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | HEXA 91/4885HEXB 116/4885DHFR 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.